BUY Aurobindo Pharma — Swati Hotkar, Nirmal Bang Securities
bySwati Hotkar, Nirmal Bang SecuritiesHorizon: 1–3 months1 Apr 2026via NDTV Profit
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Aurobindo Pharma USA Inc., a subsidiary of Aurobindo Pharma, has completed the acquisition of Lannett.
NSE · Acquisition·30 Jun · yesterday
Aurobindo Pharma Ltd has announced the completion of an acquisition.
BSE · Company Update·25 Jun · 5d ago
Aurobindo Pharma has completed the execution of a solar power purchase agreement and acquired a 26% stake in Swarnaakshu Solar Power Private Limited for Rs. 52 lakhs. The company plans further investm
NSE · Acquisition·25 Jun · 5d ago
3 advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · adjacent horizon·25 Jun · 6d ago
Aurobindo Pharma USA has received approval from the FTC to acquire Lannett Company, a significant strategic move for the company.
NSE · Press Release·22 Jun · 1w ago
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.